Interferon‐β1b treatment modulates cytokines in patients with primary progressive multiple sclerosis

@article{Dressel2006Interferon1bTM,
  title={Interferon‐$\beta$1b treatment modulates cytokines in patients with primary progressive multiple sclerosis},
  author={Alexander Dressel and A. K. Kolb and Ercan Dr.Med. Elitok and Andreas Bitsch and Timon Bogumil and Bernd Kitze and Hayrettin Tumani and Frank Weber},
  journal={Acta Neurologica Scandinavica},
  year={2006},
  volume={114}
}
Objectives –  It is unknown whether the immunological effects of β‐interferon (IFN‐β) differ in primary progressive multiple sclerosis (PPMS) when compared with relapsing–remitting multiple sclerosis (RRMS). Therefore, we investigated the effects of IFN‐β1b treatment in PPMS on proliferation and cytokine pattern of peripheral blood mononuclear cells (PBMC) and interleukin‐10 (IL‐10) serum level. 
MxA protein – an interferon beta biomarker in primary progressive multiple sclerosis patients
TLDR
Myxovirus resistance protein A (MxA) – a marker ofIFNβ bioactivity – was correlated with the clinical response during an uncontrolled trial, investigating the safety of IFNβ‐1b in primary progressive (PPMS) patients.
Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.
TLDR
Results of the study suggest that CinnoVex and Avonex modulate the immune system less than Rebif® and Betaferon® in MS patients, and an elevated dose of Cinni Vex andAvonex may be required for better regulation of the immune System in MS Patients.
Association of -592 region of IL-10 polymorphisms with asthma in south-eastern Iranian patients.
TLDR
It can be concluded that the IL-10 promoter polymorphisms may play a crucial role in the pathogenesis of asthma.

References

SHOWING 1-10 OF 41 REFERENCES
Interferon‐β therapy for multiple sclerosis induces reciprocal changes in interleukin‐12 and interleukin‐10 production
TLDR
These effects, observed equally in patients with relapsing‐remitting and progressive disease, indicate that interferon‐β affects the interleukin‐12/interleuk in‐10 axis in ways thought to be beneficial to multiple sclerosis patients.
The effects of interferon-beta on interleukin-10 in multiple sclerosis patients.
TLDR
The ability of inducing anti-inflammatory cytokine IL-10 plays a role in the clinical advantage of IFN-beta 1b in MS treatment and results support that this drug has therapeutic effects in the treatment of MS patients.
Interferon-β-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis
TLDR
The suppression of MMP-9 by IFN-β1b indicates that this drug is immunomodulatory active in PPMS patients, and further studies are necessary to test if IFn-β exerts a beneficial effect in PP MS.
Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease
TLDR
It is demonstrated that patients with PPMS express less pro- and more anti-inflammatory cytokine producing T cells compared to the relapse-onset form of the disease, confirming the view on PPMS as a distinct disease entity.
Interferon-beta sub 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis
TLDR
IFN-beta1b (Betaseron) decreases CD3-mediated TNF-alpha secretion but increases another inflammatory cytokine, IL-6, that could potentially counteract its beneficial immunomodulatory effects.
Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
TLDR
The suppression of MMP-9 by IFN-beta1b indicates that this drug is immunomodulatory active in PPMS patients, and demonstrates that the M MP-9 to TIMP-1 ratio in patients with PPMS is elevated in comparison with healthy controls.
Interferon β-1a in primary progressive MS
TLDR
This study has demonstrated that interferon β-1a 30 μg was well tolerated, identified useful outcome measures, but showed no efficacy on the primary outcome measure or on most of the secondary outcome measures.
...
...